Roche Holding AG Bearer Shares RO

Morningstar Rating
CHF 411.00 −3.20 (0.77%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RO is trading at a LOCK|Y@?p premium.
Price
CHF 414.20
Fair Value
LOCK|p.$kB@Mb
Uncertainty
LOCK|yBl!X
1-Star Price
LOCK|K.?GPNbC
5-Star Price
LOCK|D.#F%>cx
Economic Moat
LOCK|L?F
Capital Allocation
LOCK|MP@%tv

News

Trading Information

Previous Close Price
CHF 414.20
Day Range
CHF 409.80–415.00
52-Week Range
CHF 301.20–417.80
Bid/Ask
CHF 408.00 / CHF 0.00
Shares Outstanding
796.77M
Market Cap
CHF 327.47B
Volume/Avg
27,206 / 29,753

Key Statistics

Price/Earnings (Normalized)
22.37
Price/Sales
5.26
Dividend Yield (Trailing)
2.38%
Dividend Yield (Forward)
2.38%
Dividend Payment Schedule
Mar
Total Yield
2.38%

Company Profile

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
112,774

Competitors

Valuation

Metric
RO
REGN
ABBV
Price/Earnings (Normalized)
22.3718.8433.19
Price/Book Value
10.022.96—
Price/Sales
5.266.057.86
Price/Cash Flow
16.4617.4822.09
Price/Earnings
RO
REGN
ABBV

Financial Strength

Metric
RO
REGN
ABBV
Quick Ratio
0.802.720.56
Current Ratio
1.233.350.87
Interest Coverage
13.49106.895.20
Quick Ratio
RO
REGN
ABBV

Profitability

Metric
RO
REGN
ABBV
Return on Assets (Normalized)
15.81%14.40%16.61%
Return on Equity (Normalized)
48.77%18.83%—
Return on Invested Capital (Normalized)
23.90%15.64%36.97%
Return on Assets
RO
REGN
ABBV

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|N$^yH^#RLOCK|$$k$1T
Johnson & Johnson
JNJ
LOCK|$<$BR$LOCK|XM$671B
AbbVie Inc
ABBV
LOCK|$<f!#CtLOCK|$p^$518B
Roche Holding AG ADR
RHHBY
LOCK|Nxd&@&&cLOCK|@&h$386B
Merck & Co Inc
MRK
LOCK|fpg^^XLOCK|^<$353B
Novartis AG ADR
NVS
LOCK|l#YJWr^MLOCK|F#$300B
AstraZeneca PLC
AZN
LOCK|!%<H<X$?LOCK|xk$288B
Amgen Inc
AMGN
LOCK|fHr$YC!!LOCK|vJJ$248B
Gilead Sciences Inc
GILD
LOCK|R>&LWr#LOCK|L&$211B
Novo Nordisk AS ADR
NVO
LOCK|KP&^^ChLOCK|Sf$179B

Sponsor Center